Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis.
In: Hormone & Metabolic Research, Jg. 55 (2023-12-01), Heft 12, S. 827-834
academicJournal
Zugriff:
The clinical relevance of bone metastases (BM) in advanced pancreatic neuroendocrine tumors (PanNETs) is poorly described. We analyzed 314 consecutive PanNET patients treated at the European Neuroendocrine Tumour Society (ENETS) Center Essen between 2009 and 2021 in terms of the occurrence and clinical and prognostic impact of BM using hybrid imaging with 68Ga-DOTATOC PET/CT. According to UICC staging, 171/314 (54.5%) patients had stage IV PanNETs. BM was diagnosed in 62/171 (36.3%) patients. Initially, 35% of BMs were visible by pathological tracer uptake only. Skeletal-related events (SREs) were detected in 11 of the 62 patients (17.7%). Patients with antiresorptive therapy had a significantly lower rate of SRE (2/36, 5.6%) than individuals without bone-specific therapy (9/26, 34.6%) (odds ratio 9.0, p=0.0054, Fisher's exact test). The median overall survival (OS) was 82 months (53.6–110.4, 95% CI) in the stage IV PanNET cohort. The median OS was significantly lower for patients with BM (63 months; 49.9–76.0, 95% CI) than for patients with distant metastases other than BM (116 months; 87.6–144.3, 95% CI) (p=0.016, log-rank test). BM occurs in more than one-third of advanced PanNETs and is associated with an unfavorable prognosis. One in five patients experiences a persistent quality-of-life-lowering SRE. Antiresorptive therapy is associated with a more favorable risk of SREs and should be offered to all patients with BM in PanNETs. [ABSTRACT FROM AUTHOR]
Copyright of Hormone & Metabolic Research is the property of Georg Thieme Verlag Stuttgart and its content may not be copied or emailed to multiple sites or posted to a listserv without the copyright holder's express written permission. However, users may print, download, or email articles for individual use. This abstract may be abridged. No warranty is given about the accuracy of the copy. Users should refer to the original published version of the material for the full abstract. (Copyright applies to all Abstracts.)
Titel: |
Bone Metastases in Patients with Pancreatic NETs: Prevalence and Prognosis.
|
---|---|
Autor/in / Beteiligte Person: | Mathew, Annie ; Fendler, Wolfgang P. ; Theysohn, Jens ; Herrmann, Ken ; Führer, Dagmar ; Lahner, Harald |
Zeitschrift: | Hormone & Metabolic Research, Jg. 55 (2023-12-01), Heft 12, S. 827-834 |
Veröffentlichung: | 2023 |
Medientyp: | academicJournal |
ISSN: | 0018-5043 (print) |
DOI: | 10.1055/a-2159-5548 |
Schlagwort: |
|
Sonstiges: |
|